Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Cisplatin and carboplatin induce ototoxicity manifested as sensorineural hearing loss,
tinnitus, and/or vestibular disturbances. Ototoxicity is induced via damage to inner ear
structures by reactive oxygen species. Previous animal studies demonstrated that
transtympanic injection of Ringer's Lactate (RL) provided near complete otoprotective effect
against cisplatin. The purpose of this study is to determine if transtympanic administration
of Ringer's Lactate via a pressure equalising (PE) tube in patients undergoing platinum based
chemotherapy treatment will prevent tinnitus, vestibular dysfunction and hearing loss
especially at high frequencies. Pre- and post- chemotherapy treatment audiometry will be
measured and statistically analysed for significance.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre